Swiss food giant Nestlé has said it wants to take full ownership of Seres Therapeutics’ Vowst microbiome therapy for Clostridiodes difficile infections (CDI), upgrading its current co-marketing ...
Research has shown spores of Clostridioides difficile, commonly known as C. diff, are completely unaffected despite being treated with high concentrations of bleach used in many hospitals. The study's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results